Sandbox:Sahar: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
{| class="wikitable" | {| class="wikitable" | ||
!Organ System Involvement | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Organ System Involvement}} | ||
!Differential Diagnosis | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Differential Diagnosis}} | ||
!Causes | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Causes}} | ||
!Clinical Features | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Clinical Features}} | ||
!Laboratory Findings | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Laboratory Findings}} | ||
!Gold Standard Test | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Gold Standard Test}} | ||
!Therapy | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Therapy}} | ||
|- | |- | ||
| rowspan="9" |'''Nephrotic Syndrome and Renal Failure''' | | rowspan="9" |'''Nephrotic Syndrome and Renal Failure''' | ||
|Secondary (AA) Amyloidosis | |'''[[Secondary (AA) Amyloidosis]]''' | ||
| | | | ||
* Chronic inflammatory disorders | * Chronic [[inflammatory disorders]] | ||
* Chronic infections | * Chronic [[infections]] | ||
| | | | ||
* Periorbital edema | * [[Periorbital edema]] | ||
* Lower extremity edema | * [[Lower extremity edema]] | ||
* Signs/symptoms of underlying inflammatory disorder | * [[Signs]]/[[symptoms]] of underlying inflammatory disorder | ||
| | | | ||
* Proteinuria | * Proteinuria | ||
* Elevated level of [[acute phase reactant]] due to underlying inflammatory condition | * Elevated level of [[acute phase reactant]] due to underlying inflammatory condition | ||
| | | | ||
* | * Biopsy and congo-red staining of the sample | ||
| | | | ||
* Treatment of the undelying [[iflammatory disorder]] | |||
|- | |- | ||
|Primary (AL) Amyloidosis | |'''[[Primary (AL) Amyloidosis]]''' | ||
| | | | ||
* [[Monoclonal]] [[plasma cell]] proliferation | * [[Monoclonal]] [[plasma cell]] proliferation | ||
Line 66: | Line 63: | ||
* [[Kidney transplantation]] | * [[Kidney transplantation]] | ||
|- | |- | ||
|[[Diabetic nephropathy|Diabetic Nephropathy]] | |'''[[Diabetic nephropathy|Diabetic Nephropathy]]''' | ||
| | | | ||
* Hyperfiltration | * Hyperfiltration | ||
Line 91: | Line 88: | ||
* [[Glycemic]] control | * [[Glycemic]] control | ||
|- | |- | ||
|[[Minimal change disease|Minimal Change Disease]] | |'''[[Minimal change disease|Minimal Change Disease]]''' | ||
| | | | ||
* [[Upper respiratory tract infection]] | * [[Upper respiratory tract infection]] | ||
Line 120: | Line 117: | ||
* Salt restriction | * Salt restriction | ||
|- | |- | ||
|[[Focal segmental glomerulosclerosis|Focal Segmental Glomerulosclerosis]] | |'''[[Focal segmental glomerulosclerosis|Focal Segmental Glomerulosclerosis]]''' | ||
| | | | ||
* [[HIV]] | * [[HIV]] | ||
Line 156: | Line 153: | ||
* [[Mycophenolate|Mycophenolate motefil]] | * [[Mycophenolate|Mycophenolate motefil]] | ||
|- | |- | ||
|[[Fabry's disease|Fabry's Disease]] | |'''[[Fabry's disease|Fabry's Disease]]''' | ||
| | | | ||
* Deficient alpha galactosidase A | * Deficient alpha galactosidase A | ||
Line 179: | Line 176: | ||
* [[Migalastat]] | * [[Migalastat]] | ||
|- | |- | ||
|Light Chain Deposition Disease | |'''Light Chain Deposition Disease''' | ||
| | | | ||
* [[Multiple myeloma]] | * [[Multiple myeloma]] | ||
Line 203: | Line 200: | ||
* [[Kidney transplantation|Kidney transplant]] | * [[Kidney transplantation|Kidney transplant]] | ||
|- | |- | ||
|[[Membranous glomerulonephritis|Membranous Glomerulonephritis]] | |'''[[Membranous glomerulonephritis|Membranous Glomerulonephritis]]''' | ||
| | | | ||
* [[Hepatitis B]] and [[Hepatitis C|C]] | * [[Hepatitis B]] and [[Hepatitis C|C]] | ||
Line 244: | Line 241: | ||
* [[Rituximab]] | * [[Rituximab]] | ||
|- | |- | ||
|Fibrillary-Immunotactoid Glomerulopathy | |'''Fibrillary-Immunotactoid Glomerulopathy''' | ||
| | | | ||
* [[Idiopathic]] | * [[Idiopathic]] | ||
Line 261: | Line 258: | ||
| | | | ||
|- | |- | ||
!Organ System Involvement | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Organ System Involvement}} | ||
!Differential Diagnosis | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Differential Diagnosis}} | ||
!Causes | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Causes}} | ||
!Clinical Features | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Clinical Features}} | ||
!Laboratory Findings | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Laboratory Findings}} | ||
!Gold Standard Test | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Gold Standard Test}} | ||
!Therapy | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Therapy}} | ||
|- | |- | ||
| rowspan="6" |''Polyneuropathy'' | | rowspan="6" |'''Polyneuropathy''' | ||
|'''[[POEMS syndrome]] (Demyelinating)''' | |'''[[POEMS syndrome]] (Demyelinating)''' | ||
| | | | ||
Line 424: | Line 421: | ||
* [[Rituximab]] | * [[Rituximab]] | ||
|- | |- | ||
|'''Organ System Involvement''' | | style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Organ System Involvement'''}} | ||
|'''Differential Diagnosis''' | | style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Differential Diagnosis'''}} | ||
|'''Causes''' | | style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Causes'''}} | ||
|'''Features''' | | style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Features'''}} | ||
|'''Laboratory Findings''' | | style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Laboratory Findings'''}} | ||
|'''Gold Standard Test''' | | style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Gold Standard Test'''}} | ||
|'''Therapy''' | | style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Therapy'''}} | ||
|- | |- | ||
| rowspan="7" |''Organomegaly (Hepatosplenomegaly and Lymphadenopathy)'' | | rowspan="7" |'''Organomegaly (Hepatosplenomegaly and Lymphadenopathy)''' | ||
|'''[[Malaria]]''' | |'''[[Malaria]]''' | ||
| | | |
Revision as of 22:12, 4 November 2019
Organ System Involvement | Differential Diagnosis | Causes | Clinical Features | Laboratory Findings | Gold Standard Test | Therapy |
---|---|---|---|---|---|---|
Nephrotic Syndrome and Renal Failure | Secondary (AA) Amyloidosis |
|
|
|
|
|
Primary (AL) Amyloidosis |
|
|
|
|||
Diabetic Nephropathy |
|
|
|
|||
Minimal Change Disease |
|
| ||||
Focal Segmental Glomerulosclerosis | ||||||
Fabry's Disease |
|
|
|
|
| |
Light Chain Deposition Disease |
|
|
| |||
Membranous Glomerulonephritis |
|
|
|
|
| |
Fibrillary-Immunotactoid Glomerulopathy |
|
|
|
|||
Organ System Involvement | Differential Diagnosis | Causes | Clinical Features | Laboratory Findings | Gold Standard Test | Therapy |
Polyneuropathy | POEMS syndrome (Demyelinating) |
|
|
|||
Metabolic Syndrome (Axonal pathology) |
|
|
|
|||
Vitamin Deficiencies (Axonal Pathology) |
|
|
|
| ||
Guillain-Barre Syndrome (Demyelinating) |
|
|
|
|||
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Mixed axonal and demyelinatiing) |
|
|
|
|
||
Multifocal Motor Neuropathy |
|
|||||
Organ System Involvement | Differential Diagnosis | Causes | Features | Laboratory Findings | Gold Standard Test | Therapy |
Organomegaly (Hepatosplenomegaly and Lymphadenopathy) | Malaria |
|
|
| ||
Kala-azar |
|
|
|
|||
Infective Hepatitis |
|
|
||||
Chronic Myelogenous Leukemia (CML) |
|
|
||||
Lymphoma |
|
|
||||
Primary (AL) Amyloidosis |
|
|
|
| ||
Gaucher's Disease |
|
|
|
|
Example #1
The patient presented with S.O.B. one year after hysterectomy for a leiomyomatous uterus.